Vaccines for Cancer Immunotherapy

Professor Nima Rezaei gained his medical degree (MD) from Tehran University of Medical Sciences and subsequently obtained an MSc in Molecular and Genetic Medicine and a PhD in Clinical Immunology and Human Genetics from the University of Sheffield, UK. He also spent a short-term fellowship of Pediatric Clinical Immunology and Bone Marrow Transplantation in the Newcastle General Hospital. Professor Rezaei is now the Full Professor of Immunology and Vice Dean of Research, School of Medicine, Tehran University of Medical Sciences, and the co-founder and Head of the Research Center for Immunodeficiencies. He is also the founding President of the Universal Scientific Education and Research Network (USERN). Professor Rezaei has already been the Director of more than 55 research projects and has designed and participated in several international collaborative projects. Professor Rezaei is an editorial assistant or board member for more than 30 international journals. He has edited more than 35 international books, has presented more than 500 lectures/posters in congresses/meetings, and has published more than 1,000 scientific papers in the international journals. Mahsa Keshavarz-Fathi is a medical researcher and MD candidate at Tehran University of Medical Sciences (TUMS). She is also the managing director of the Cancer Immunology Project (CIP) and Breast Cancer Association (BrCA) undertaking and managing different research projects in the field of cancer treatment, cancer immunology and immunotherapy.

• 1. Cancer immunology2. Immunotherapeutic Approaches in Cancer3. Vaccines, Adjuvants, and Delivery Systems4. Tumor Antigens 5. Strategy of Allogeneic and Autologous Cancer Vaccines6. Personalized Cancer Vaccine7. Whole Tumor Cell Vaccine for Cancer8. Peptide and Protein Vaccines for Cancer9. Immune Cell Vaccine for Cancer10. Genetic Vaccine for Cancer11. Candidate Cancers for Vaccination12. Obstacles in the Development of Therapeutic Cancer Vaccines13. Combination Therapy: Cancer Vaccines and Other Therapeutics14. Concluding Remarks and Future Perspectives on Therapeutic Cancer Vaccines